Infliximab and tocilizumab reduce anxiety-like behavior, improve cognitive performance and reverse neuropathological alterations in juvenile rats with severe autoimmune arthritis.

Autor: Poutoglidou F; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus 54124 Thessaloniki, Greece. Electronic address: friderikipa@yahoo.gr., Pourzitaki C; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus 54124 Thessaloniki, Greece., Manthou ME; Laboratory of Histology and Embryology, School of Medicine, Aristotle University of Thessaloniki, University Campus 54124 Thessaloniki, Greece., Saitis A; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus 54124 Thessaloniki, Greece., Malliou F; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus 54124 Thessaloniki, Greece., Kouvelas D; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus 54124 Thessaloniki, Greece.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2021 Oct; Vol. 99, pp. 107917. Date of Electronic Publication: 2021 Jul 01.
DOI: 10.1016/j.intimp.2021.107917
Abstrakt: Several studies have demonstrated that rheumatic diseases, including Juvenile Idiopathic Arthritis (JIA), are associated with anxiety-like behavior and a cognitive decline. Infliximab, a Tumor Necrosis Factor-alpha (TNF-a) inhibitor, and tocilizumab, an antibody against Interleukin-6 (IL-6) receptor, are commonly used in the treatment of JIA. Here, we aimed to evaluate the effects of infliximab and tocilizumab on anxiety symptoms and cognitive function in a juvenile model of severe autoimmune arthritis. We found that both infliximab and tocilizumab improved anxiety-like behavior in the elevated-plus and elevated-zero maze tests. Tocilizumab, also, improved cognitive performance in the passive avoidance and olfactory social memory tests. Histological examination showed that anti-cytokine treatment reversed the histopathological alterations in the brain induced by arthritis. Further, infliximab and tocilizumab treatment increased Brain-Derived Neurotrophic Factor (BDNF) expression in the hippocampal and amygdaloid area of rat brain. In summary, our findings provide evidence that infliximab and tocilizumab have a beneficial effect on anxiety-like behavior and cognitive function and alleviate neuropathological alterations in a juvenile rat model of severe arthritis, suggesting that inhibition of TNF-a and IL-6 in the periphery, may be associated with a mood and memory enhancement in JIA patients.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: